CD8A and cancer: To be efficacious, peptide-based cancer vaccines must have CD8+ T cell epitopes to activate cytotoxic T lymphocytes (CTL) antitumor immunity via the antigen cross-presentation pathway, as well as CD4+ T cell epitopes to activate T helper cells, which sustain CTL effector functions [42].